button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

versus ipilimumab alone
pembrolizumab (10mg/kg) vs. ipilimumab alone 1 certainty unassessablestatistically conclusive-29% certainty unassessablestatistically conclusive-39%-
pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone 1 certainty unassessablestatistically conclusive-34% certainty unassessablestatistically conclusive-39%-
versus Standard of Care (SoC)
nivolumab alone vs. Standard of Care (SoC) 1 certainty unassessable-5% certainty unassessable+3%-
pembrolizumab (10mg/kg) vs. Standard of Care (SoC) 1 certainty unassessable-24% certainty unassessablestatistically conclusive-46%-
pembrolizumab (2mg/kg) vs. Standard of Care (SoC) 1 certainty unassessable-13% certainty unassessablestatistically conclusive-40%-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons